2024 Financial Report | Profit growth hit its lowest level in 10 years. Is Changchun Gaoxin's growth hormone ceiling here?
The time for the “first strain of growth hormone” to slow down has arrived. On March 20, Changchun Hi-Tech (000661.SZ) released its 2023 financial report, showing that current revenue and net profit to mother were 14.566 billion yuan and 4.532 billion yuan respectively, up 15.35% and 9.47% year-on-year respectively. This net profit growth rate to mother hit a record low since 2014. On March 20, Changchun Hi-Tech closed down 2.57%. Specifically, the current revenue and net revenue of Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as “Jinsai Pharmaceutical”), the core subsidiary responsible for growth hormone under Changchun Hi-Tech
2024 Financial Report | BGI's profit fell by more than 80%, making it difficult to find the next outlet
The era of gold everywhere is over
Suspected to be hyped up by the “Lhasa Gang”, and illegal repurchases were unstopped*ST Meisheng stepped out of the quadruplex
Hit the drums and spread the flowers.
Net profit increased 55%-70%, and the three squirrels still had to rely on the old e-commerce business to “turn over” | Insight Research
When prices are low everywhere, price is no longer the biggest advantage.
Meibang Apparel “sells houses to survive”: since last year, the total number of re-stores is expected to reach 1.3 billion
How can established casual wear be saved?
“Yemao” Tongze Healthcare's revenue growth in the third quarter was close to stagnation, and net profit fell 5.58% year on year | Financial News
Tongce Medical's revenue for the first three quarters was 2.85 billion yuan, up 2.12% year on year; net profit to mother was 512 million yuan, a decrease of 0.67% year on year.